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1. Introduction 
Peptides show great pharmaceutical potential as active drugs and diagnostics in several 
clinical areas such as endocrinology, urology, obstetrics, oncology, etc. and as functional 
excipients in drug delivery systems to overcome tissue and cellular membrane barriers 
(Nestor, 2009). From a pharmaceutical point of view, peptides are situated somewhere 
between classical organic drug substances and high molecular weight biopharmaceuticals. 
The importance of peptides to life is evident from the most primitive organism to man. In 
man, a myriad of roles is filled by peptides spanning hormonal, neuromodulatory, mucosal 
defense, et al.  
Despite the obvious importance of peptides to homeostasis in man, there are few peptides 
resulting from medicinal chemistry that are commercialized pharmaceutical products in the 
USA and Europe. The shortcomings of peptides as pharmaceutical products have been long 
known: typically short duration of action, lack of receptor subtype selectivity, lack of oral 
bioavailability. However medicinal chemistry offers solutions to the first two limitations and 
oral bioavailability issues have been addressed by novel routes of administration (e.g. 
intranasal, inhalation) and injectable depot formulations (Nestor, 2009). 
2. Peptide design considerations 
The physical and chemical properties of peptides and proteins are determined by the nature 
of the constituent amino acid side chains and by the polyamide peptide backbone itself.  
The structures of the 20 primary amino acids are given in Figure 1. Amino acids are divided 
into hydrophobic and hydrophilic residues. The first group includes those with aliphatic 
side chains (Ala, Val, Ile, Leu, Met) and those with aromatic side chains (Phe, Tyr, Trp). The 
hydrophilic group includes amino acids with neutral, polar side chains (Ser, Thr, Asn, Gln), 
those with acidic (Asp and Glu) or with basic side chains as Lys, Arg and His. 
Two amino acids, Cys and Pro, have special properties that set them apart. Cys containing a 
thiol group that can be oxidatively couple to another Cys residue to form a disulfide bond 
that stabilizes secondary and/or tertiary structure or to hold two different peptide chains 
together. On the other hand, free thiols are present in some protein, where they serve as 
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ligand for metal chelation, as nucleophiles in proteolitic enzymes, or as carboxyl activators 
in acyl transferases. Pro is a cyclic residue that has specific conformational effects on the 
peptide or protein backbone. Indeed, cyclic structure locks Pro Ǘ backbone dihedral angle at 
approximately -75°. Additionally, several residues can undergo post-traslational 
modification to yield new amino-acids. 
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Fig. 1. L-Amino acid structures. 
Small peptides typically show high conformational flexibility due to the multiple 
conformations that are energetically possible for each residue. The conformation of the 
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peptide backbone can be described by three torsional angles (Figure 2): Ǘ, which is the angle 
defined by C(O)—N—Cǂ—C(O); Ǚ, which is defined by N—Cǂ—C(O)—N; and ǚ, which is 
defined by Cǂ—C(O)—N—Cǂ. The ǚ angle for the peptide bond is generally trans (ǚ = 
180°) except for the Xaa-Pro bond, which can be cis (ǚ = 0°) or trans. Pioneering work of 
Ramachandran et al. (1965) resulted in the so-called Ramachandran plots which restrict the 
allowed values for the torsional angles Ǘ and Ǚ to most amino acids. The conformational 
space accessible to the L-amino acids is about one third of the total structural space. 
Nevertheless the remaining degrees of freedom still make a prediction of structure 
extremely difficult. There are only few examples reported in the literature where short to 
medium sized peptides (<30-50 residues) adopt a stable structures in aqueous solution 
(Grauer & Köning, 2009). In most cases they exist in numerous dynamically interconverting 
conformations. 
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Fig. 2. (A) Backbone and side chain torsional angles; (B) Newman projection of three 
staggered rotamers in L-amino acids. 
An equally critical area for the design of bioactive peptides, though much less explored, is 
that of the three-dimensional structures of the side chain moieties. This is described by the 
side chain ǘ torsional angle (ǘ1 is defined by the N-Cǂ-Cǃ-CǄ) (Figure 2). It can assume three 
low energy staggered conformations (rotamers): gauche(+); gauche(-); and trans. The energy 
differences between these conformations is not high, but the orientation of the side chain 
group of an L-amino acid residue relative to the peptide backbone is dramatically different: 
for gauche(-) ǘ1, the side chain points toward the N-terminus of the peptide chain; for trans, 
the side chain points toward the C-terminus; and for gauche(+), the side chain points over 
the peptide backbone (Hruby et al., 1997). The consequences for both the surface that is 
created by the peptide ligand and its complimentarity for a receptor/acceptor are critical for 
successful recruitment of the target from small peptides as confirmed by structure-activity 
relationship studies (Hruby et al., 1997). 
A 
B 
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The most important technique for structural determination of biomolecules is the x-ray 
diffraction analysis on single crystal, even if it is questionable whether the solid state 
conformation determined by X-ray analysis are identical to those occurring in solution or 
during the interactions with the biological target (Kessler, 1982; Wuthrich et al, 1991). Over the 
last decade, NMR spectroscopy has emerged as an important tool for structural determination 
of biomolecule in solution. The increase in magnet technology and in the speed and data 
storage capacity of modern PCs allowed the development of multi-dimensional NMR methods 
which permit to solve in detail the resonance assignment of biomolecules and to determine 
proton-proton distances at the base of NMR structures determination. 
In addition to these powerful techniques, also fluorescence and circular dichroism (CD) 
studies provide useful information about the peptide conformation in solution and its 
capability to interact with target molecules (Ruzza, 2001; Siligardi, 2011). 
2.1 Methodologies for design peptides 
Conformational considerations in peptide synthesis remain one of the greatest challenges in 
the design of biologically active peptides. Peptides will usually be an ensemble of 
conformation states in solution. If biological activity involves only one discrete conformer, 
this conformational ensemble represents a dilution of the biologically active species. 
This problem is more acute for peptides designed to mimic a portion of a protein structure, 
where the intramolecular interactions characteristic of the protein structure are lost (Figure 
3). A strategy for reducing the number of the accessible conformations and rendering the 
selectivity of synthetic peptides more stringent than that afford by the sequence could take 
advantage by the introduction of local or global constraints into peptide sequences. 
 
Fig. 3. Binding equilibrium involving a conformational manifold of the proline-rich peptide. 
The association process consists of the redistribution of the conformational ensemble from 
the binding-incompetent to the binding-competent (PPII) species, and then of the interaction 
of the latter with the SH3 domain (adapted from Ruzza et al., 2006). 
2.1.1 Global restrictions 
The simplest way to introduce a conformational constraint into a peptide sequence is by 
cyclization (Figure 4). This typically increases the in vivo stability of the cyclic peptides 
compared to their linear analogs. Cyclization can be obtained by connecting the N- with the 
C-terminus (head-to-tail) portion of the peptide sequence, or the couple of either the N- or 
the C-terminus with one of the side chains (backbone-to-side chain), or the couple of side 
chains not involved in specific interactions with other (side chain-to-side chain). 
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The most common side chain-to-side chain cyclization is the oxidation of two Cys residues 
with the formation of a disulfide bond. Alternatively, the formation of amide bonds between 
the side chains of Lys and Asp/Glu can occur. One limiting factor of side chain-to-side  
chain cyclization is that a limited section of the polypeptide is constrained. To overcome  
this problem several covalent bridges may be incorporated into one sequence (Grauer  
& Köning, 2009). 
H-Phe-Lys-Ala-Asn-Cys-Glu-Ser-Cys-Ala-OH
Phe-Lys-Ala-Asn-Cys-Glu-Ser-Cys-Ala
A
H-Phe-Lys-Ala-Asn-Cys-Glu-Ser-Cys-Ala
HN
Phe-Lys-Ala-Asn-Cys-Glu-Ser-Cys-Ala-OH
CO
B
H-Phe-Lys-Ala-Asn-Cys-Glu-Ser-Cys-Ala-OH
S S
H-Phe-Lys-Ala-Asn-Cys-Glu-Ser-Cys-Ala-OH
HN CO
C
 
Fig. 4. Examples of peptide cyclization: (A) head-to-tail, (B) backbone-to-side chain, and (C) 
side chain-to-side chain. 
2.1.2 Local restrictions 
The simplest local constraints that can be placed on a given residue involve the substitution 
of a methyl group for an hydrogen adjacent to a rotable bond (Figure 5).  One substitution 
which have been extensively investigated in the last years involve the ǂ-hydrogen yielding 
Cǂ-tetrasubstituted ǂ-amino acids (Toniolo, 2001, and reference therein). For example, 
replacing the ǂ-hydrogen on alanine with a methyl group gives ǂ-aminoisobutyric acid 
(Aib). This residue was found in peptide sequences from a fungal source. The steric bulk of 
the methyl group reduced the rotational freedom of the two peptide backbone angles Ǘ and 
Ǚ. In the case of Aib, the allowable Ǘ and Ǚ backbone angles in peptides are restricted to 
values near –57°,  -47° and +57°, +47° (Karle, 1996). 
The introduction of an alkyl group either at the ǃ-position or on aromatic ring of naturally 
occurring amino acids rigidifies the conformational flexibility of the side chain. Three  
of natural amino acids show ǃ-disubstitutions: Val (two methyl groups), Ile (a methyl  
and an ethyl) and Thr (a methyl and a hydroxyl). Additionally, ǃ-substitution leads to a 
second asymmetric center in the amino acid structure. These modifications do not greatly 
perturb the backbone, allowing the peptide backbone and the side chain some degree  
of flexibility, which often is crucial for the activity of peptide mimetic. Another advantage  
of these modifications is that the extra alkyl groups can enhance the lipophility of peptide, 
and therefore can help it to overcome membrane barrier (Hruby et al., 1997; and  
references therein).  
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Surely, the introduction of a covalent bond between the aromatic ring of an ǂ-amino acid 
residue and the peptide backbone has proven to be a useful further conformation restriction. 
For example, 1,2,3,4-tetrahydroisoquinoline carboxylic acid (Tic) is a cyclic constrained 
analog of phenylalanine (Figure 5), in which a methylene bridge is placed between the ǂ-
nitrogen, and 2’-carbon of the aromatic ring (Kazmierski & Hruby, 1988). 
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Fig. 5. Structures of some local constraints. 
N-alkylated residue, and in particular N-methylation is an important modification of the 
peptide bond that influence the conformational freedom of the peptide backbone. The steric 
constraints introduced by the N-alkyl group have also effect on the side chain freedom of 
the neighboring amino acids. Additionally, the number of inter- and intra-molecular 
hydrogen bonds decreases due to the removal of the backbone NH groups, destabilizing 
both ǂ-helix and ǃ-sheet conformations. Finally, the attached carbonyl group shows an 
increased basicity and decreased polarity. 
Oligomers of N-substituted glycines, where the side chain is attached to the amine nitrogen 
instead of the ǂ-carbon, are called ǂ-peptoids (Figure 5) (Zuckermann & Kodadek, 2009). 
The conformational change in the N-substituted glycines makes the ǂ-carbon achiral so that 
peptoids are less restricted in their spatial conformation. Neither peptoids can form 
intramolecular hydrogen bonds through backbone–backbone interactions, because of the 
lack of amide protons that help peptides stabilize both ǂ-helical structures and ǃ-sheet 
conformations. However, the same backbone structure renders the peptoids highly resistant 
to proteases. 
A further investigated group of local constraints are derivatives of the natural amino acids 
proline. Proline analogs displaying the characteristics of other amino acids are referred to as 
proline-amino acid chimeras, and have been used to study the spatial requirements for 
receptor affinity and biological activity of both natural amino acids and peptides. For 
example, ǃ-substituted-prolines such as 3-carboxyproline, 3-phenylproline, and 3-di-
methylproline combine amino acid side chain functionality with proline’s conformational 
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rigidity. In these cases, replacement of the natural amino acids in peptides by proline-amino 
acid chimeras provided better understanding of the bioactive conformations of peptides 
binding to receptors (Quancard et al., 2004; and references therein). 
2.1.3 Backbone modification 
The backbone of a peptide can be modified in various ways by isosteric or isoeletronic 
substitution (Cudic & Stawikowski, 2007; and reference therein). Figure 6 summarizes the 
most important ways to modify the peptide backbone.  
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Fig. 6. Most important peptide bond surrogates (adapted from Cudic & Stawikowski, 2007). 
Various peptidomimetics containing pseudopeptides or peptide bond surrogates, in which 
peptide bonds have been replaced with other chemical groups, are designed and 
synthesized with the aim to obtain peptide analogs with improved pharmacological 
properties. This is mainly because such approaches create an amide bond surrogate with 
defined three dimensional structures and with significant differences in polarity, hydrogen 
bonding capability and acid-base character. Also important, the structural and 
stereochemical integrities of the adjacent pair of ǂ-carbon atoms in these pseudopeptides are 
unchanged. The psi-bracket (Ǚ[ ]) nomenclature, introduced by A. Spatola (1983), is used for 
this type of modification. The introduction of such modifications to the peptide sequence is 
expected to completely prevent protease cleavage of amide bond and significantly improve 
the peptides metabolic stability. However, such modifications may also have some negative 
effects on peptides biophysical and biochemical properties, in particular their conformation, 
flexibility and hydrophobicity. Therefore, the choice of an amide bond surrogate is a 
compromise between positive effects on pharmacokinetics and bioavailability and potential 
negative effects on activity and specificity (Cudic & Stawikowski, 2007). The ability of the 
surrogate to mimic the steric, electronic and solvation properties of the amide bond is 
certainly the most important characteristic in determining the potency of pseudopeptide 
analogs. From the synthetic point of view, the methods for assembly of 
peptidosulfonamides, phosphonopeptides, oligoureas, depsides, depsipeptides, peptoids 
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and azapeptides are parallel those for standard solid-phase peptide synthesis, although 
different reagents and different coupling and protecting strategies need to be employed. 
2.2 Methodologies for peptide synthesis 
Methods for synthesizing peptides are divided into two classes: solution or liquid phase 
(classical) and solid phase (SPPS). The classical methods have evolved since the beginning of 
the last century, and they are described amply in several books and reviews (Goodman et al., 
2004; Bodansky, 1993). The SPPS was conceived and elaborated by R.B. Merrifield beginning in 
1959, and it has also been covered compressively (Merrifield, 2006; Chan and White, 2000).  
Solution synthesis retains value in large-scale manufacturing and for specialized laboratory 
application. However, the need to optimize reaction condition and purification procedures 
for the different intermediate renders this method time-consuming and laboratory-intensive. 
Consequently, most workers, now requiring peptides for their research, opt for the more 
accessible SPPS approach. 
The concept of the SPPS can be illustrated in Figure 7 where the C-terminal protected amino 
acid is attached to an insoluble polymeric support via a labile linker. Subsequently, the 
anchored peptide is extended by a series of deprotection/coupling cycles, which are 
required to proceed with high yields and fidelities. The reactions are driven to completion 
by the use of excess soluble reagents, which can be removed by simple filtration and 
washing without losses. Once peptide has been accomplished, it is necessary to release 
protected residues and to cleave the crude peptide from the solid support. These two 
operations can be performed simultaneously or in separate step, according to the successive 
destine of the peptide. Finally, the synthetic peptide must undergo purification step and 
characterization to verify the desired structure. 
The two major chemistries for SPPS involve the use of either base labile ǂ-amino protecting 
group (Fmoc) or acid labile ǂ-amino protecting group (Boc). Each method involves different 
side chain protecting group, and consequent cleavage/deprotection methods and resins 
(Table 1). 
Peptide purification and peptide quality evaluation is performed by HPLC. Most crude 
peptides are purified by reversed phase HPLC to achieve the desired purity. The 
combination of cation or anion exchange HPLC purification followed by RP-HPLC provides 
a powerful technique to purify a crude peptide with inferior quality. Mass spectra by 
MALDI or ESI-TOF and mono- and bi-dimensional NMR are the standard analytical 
procedure to assess peptide identity. 
Recently, convergent synthesis strategies for the generation of highly complex branched 
peptides or scaffolded peptides and proteins have been developed. Such ligation reactions 
include the formation of thiazolidines or oximes from mutually reactive precursors, as 
well as native chemical ligation through reaction of a peptide thioester with an N-terminal 
cysteine in aqueous buffers, or the generation of [1,2,3]-triazoles through 1,3-dipolar 
cycloadditions of alkynes to azides, which belongs to a group of reactions referred to as 
click chemistry, which proceed at room temperature in the presence of copper(I) as a 
catalyst. 
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Fig. 7. Fmoc solid-phase peptide synthesis procedure. 
 
Topic Fmoc chemistry Boc chemistry 
Side chain protection Acid sensitive Strong acid sensitive (HF) 
Nǂ-deprotection 20% piperidine in DMF 50% TFA in DCM 
Final cleavage TFA in SPPS vessel HF (special equipment) 
Automation Yes Yes 
Synthetic steps Deblock, wash, couple, wash 
Deblock, neutralization, 
wash, couple, wash 
Resin Acid or super-acid sensitive Merrifield type 
Table 1. Comparison of Fmoc- and Boc-SPPS.  
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3. Peptides and molecular recognition  
In the post-genomic era, the importance of protein-protein interactions is becoming even 
more apparent. Proteins continuously interact each other to govern signaling pathways 
within and between cells. Biological signaling requires that protein complexes are formed 
and activated at the right time and in the right place, and that their formation is both 
reversible and transient. The strength and duration of a signal may be critical for the effects 
of hormones, cytokines and growth factors, and a large number of specific protein 
interaction domains are known which mediate this machinery (Pawson, 2004).  
Although it is possible to derive some general principles of protein-protein recognition from 
experimentally determined structures, recent structural studies on protein complexes formed 
during signal transduction illustrate the remarkable diversity of interactions, both in term of 
interfacial size and nature. There are two broad classes of complexes: “domain-domain,” in 
which both components comprise pre-folded structural units, and “domain-peptide,” in which 
one component is a short motif that is unstructured in the absence of its binding partner. 
Structure-based drug design seeks to identify and modulate such interactions. This 
optimization process requires knowledge about interaction geometries and approximate 
affinity contributions of attractive interactions that can be gleaned from crystal structure and 
associated affinity data. 
3.1 Peptide-receptor ligands in cancer imaging 
Since the first histological evidence of the high expression of somatostatin receptors in 
pituitary adenomas (Reubi, 1984), many other human cancers were found to overexpress 
peptide receptors in vitro (Table 2). Based on these results, peptide receptor ligands labeled 
with different probes (radionuclides, magnetic and optical probes) have been started to be 
developed for the in vivo targeting and imaging of tumors. 
 
Receptor Tumor type 
Somatostatin 
(hSSTR1 – hSSTR5) 
Neuroendocrine, non-Hodgkin’s lymphoma, melanoma, breast, 
pancreatic, gastric, colon, prostate, lung, SCLC, MTC 
Cholecystokinin 
(CCK-A and CCK-B) 
MTC, SCLC, pancreatic, astrocytoma, ovarian 
Vasoactive Intestinal 
Peptide 
(VPAC1 and VPAC2) 
SCLC, colon, gastric, breast, pancreatic, prostate, urinary bladder, 
lymphoma, meningioma 
Neurotensin 
(NTR1 – NTR3) 
SCLC, colon, exocrine pancreatic, prostate 
Bombesin 
(BRS-1 – BRS-4) 
SCLC, glioblastoma, colorectal, gastric, prostate, ovarian, breast 
ǂvǃ3 Integrin Melanoma, neuroblastoma, breast 
ǂ-MSH 
(MC1R – MC5R) 
Melanoma 
Neuropeptide Y 
(Y1 – Y6) 
Neuroblastoma, glioblastoma, breast 
Substance P SCLC, MTC, glioblastoma, astrocytoma, breast 
Table 2. Peptide receptors overexpressed in tumors (adapted from Ruzza & Calderan, 2011). 
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The distribution and significance of the different peptide receptors as well as the properties 
and characteristics of their ligands have been discussed in manifold reviews (Bolzati, 2010; 
Lee, 2010; and references therein).  
Development of labeled peptide probes relied on isolation of naturally occurring peptides 
(Table 3), screening of synthetic or phage libraries, and structure-based rational design. 
Generally, peptide-based probes are designed starting from naturally occurring peptide 
hormones, which, excepting the indispensable amino acids involved in biological activity, 
are modified to prolong their half-lives in vivo. 
Peptide Sequence 
Somatostatin 
(14) 
H-Ala-Gly-c(Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys)-OH 
Somatostatin 
(28) 
H-Ser-Ala-Asn-Ser-Asn-Pro-Ala-Met-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-c(Cys-Lys-
Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-Cys)-OH 
Chlocystokinin 
H-Lys-Ala-Pro-Ser-Gly-Arg-Met-Ser-Ile-Val-Lys-Asn-Leu-Gln-Asn-Leu-Asp-Pro-
Ser-His-Arg-Ile-Ser-Asp-Arg-Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2 
Gastrin 
Pyr-Leu-Gly-Pro-Gln-Gly-Pro-Pro-His-Leu-Val-Ala-Asp-Pro-Ser-Lys-Lys-Gln-Gly-
Pro-Trp-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 
CCK8 H-Asp-Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2 
Minigastrin H-Leu-Glu-Glu-Glu-Glu-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 
Vasoactive 
Intestinal 
Peptide (VIP) 
H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-
Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2 
Neurotensin Pyr-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu-OH 
Bombesin Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 
Gastrin 
Releasing 
Peptide 
H-Val-Pro-Leu-Pro-Ala-Gly-Gly-Gly-Thr-Val-Leu-Thr-Lys-Met-Tyr-Pro-Arg-Gly-
Asn-His-Trp-Ala-Val-Gly-His-Leu-Met-NH2 
Neuromedin B H-Gly-Asn-Leu-Trp-Ala-Thr-Gly-His-Phe-Met-NH2 
RGD c[Arg-Gly-Asp-D-Phe-Lys] 
ǂ-MSH Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 
ǃ-MSH H-Ala-Glu-Lys-Lys-Asp-Glu-Gly-Pro-Tyr-Arg-Met-Glu-His-Phe-Arg-Trp-Gly-Ser-
Pro-Pro-Lys-Asp-OH 
Ǆ-MSH H-Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Arg-Phe-NH2 
ACTH 
H-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-
Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu-
Glu-Phe-OH 
GLP-1 
H-His-Asp-Glu-Phe-Glu-Arg-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-
Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg-NH2 
Neuro Peptide 
Y 
H-Tyr-Pro-Ser-Lys-Pro-Asp-Asn-Pro-Gly-Glu-Asp-Ala-Pro-Ala-Glu-Asp-Met-Ala-
Arg-Tyr-Tyr-Ser-Ala-Leu-Arg-His-Tyr-Ile-Asn-Leu-Ile-Thr-Arg-Gln-Arg-Tyr-NH2 
Calcitonin 
H-c(Cys-Gly-Asn-Leu-Ser-Thr-Cys)-Met-Leu-Gly-Thr-Tyr-Thr-Gln-Asp-Phe-Asn-
Lys-Phe-His-Thr-Phe-Pro-Gln-Thr-Ala-Ile-Gly-Val-Gly-Ala-Pro-NH2 
Table 3. Peptide receptor ligand sequences. 
A linker is usually introduced between the imaging probe and the ligand, with the aim to 
preclude or minimize unwanted interferences between these two moieties. Linkers may act 
as a pharmacokinetic modifier and have a profound impact on the biodistribution of the 
whole molecule (Rufini, 2006; Schottelius, 2004). The most popular linkers are short amino 
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acid sequences (i.e., dimer o trimer of ǃ-Ala, Gly or Nε-amino hexanoic acid) or low 
molecular weight polyethylene glycole (PEG) or hydrocarbon chains. Lipophilic molecules 
are cleared from the body by the hepatobiliary route, whereas hydrophilic probes are 
mainly cleared via the renal system. 
Natural occurring peptide-ligands are usually recognized by more than one receptor 
subtype. A great debate is ongoing about the opportunity to increase the ligand-specificity 
towards receptor subtypes expressed on tumor cells. Several studies demonstrated that 
there are significant variations in the expression profile of subtype peptide receptors also 
between the primary tumor and its metastases or even within the same tumor (Reubi, 2002; 
Reubi, 2003) and so, an increase of receptor subtypes selectivity might be counterproductive 
in the development of imaging molecules. On the other hand, subtype-selective ligands are 
useful tools for functional imaging purposes as well as to study the changes in receptor 
expression and response to therapeutic interventions. 
Until recently the use of receptor-antagonists has not been considered for in vivo targeting 
of tumors overexpressing G-protein coupled receptors and this due to the low capability of 
antagonist to internalize into tumor cells. Indeed, the cell internalization of imaging probes 
has been regarded for a long time as a fundamental prerequisite of labeled peptides, 
providing high contrast imaging. Recently, interesting results have been obtained with two 
somatostatin antagonists towards SST2 and SST3 receptor subtypes, which showed high 
tumor accumulation and retention, resulting in matchless imaging properties (Ginj, 2006). 
The benefit of the use of antagonist peptide ligands has a considerable impact on those 
systems, in which the binding of agonist-ligand either stimulates tumor growth or exerts 
unwanted pharmacological action. 
Many authors have demonstrated that different peptide receptors are co-expressed on 
tumors in a heterogeneous manner, e.g., breast cancer (expressing concomitantly GRP- and 
NPY-receptors), gastrointestinal stromal tumor (GRP, CCK-B, and VPAC2 receptors), 
gastroenteropancreatic neuroendocrine tumors (GLP-1, CCK, and VPAC1 receptors), and 
the prostate cancer (prostate-specific membrane antigen or PSMA, and integrin or GRP 
receptors) (Ruzza & Calderan, 2011). These suggest that targeting more than one receptor 
class simultaneously would greatly enhance the sensitivity of tumor detection. In addition, 
some peptide receptors (e.g., ǂvǃ3 integrin) are characterized by a low ligand internalization 
capacity, which improves in the presence of multimer ligands (Liu, 2010). 
These aspects (co-expression on tumors and low internalization capacity) stimulate the 
development of multivalent and/or multireceptor ligands able to bind either to multiple 
homo (multivalent) or to hetero (multireceptor) receptors present on the surface of the 
tumor cell. The presence of more ligands induces a number of peculiar biological 
characteristics to the targeting molecules that are not present in the monovalent ligand. 
Polyvalent interactions are generally much stronger than the corresponding monovalent 
and offer the basis for mechanisms of agonizing or antagonizing biological activities that are 
fundamentally different from those available in monovalent system. Multivalent 
interactions may become particularly attractive and biologically relevant when the ligand-
receptor binding is weak or the receptor density is low.  
Linkers and/or scaffolds structure is important because it must present ligands 
simultaneously to their cognate receptors with minimal entropic penalty. The development 
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of suitable linkers and/or scaffold structures, permitting the correct simultaneous 
presentation of ligands to their receptors, as well as the choice of opportune ligands for 
multivalency and/or multireceptor approaches may provide both new targets and strategies 
for designing new imaging agents. 
3.2 Peptides in protein-protein interactions: The SH3 domain 
From the huge array of “domain-peptide” complex class, a super-family of small domains is 
represented by the SH3 domains that it is identified in more than 350 different proteins in 
organisms ranging from yeasts to humans, showing a completely conserved structure. 
The SH3 domain is a 60-amino acids non-catalytic protein domain identified in the sequence 
similarity region between the Src and Abl families of non-receptor tyrosine kinases (Mayer, 
1988). This domain is structured on five ǃ-strands arranged into two sheets packed at right 
angle. The first sheet is formed by strands A, E and the first half of B, while the second is 
formed by ǃ-strands C, D, and the second half of B. The ǃA-strand is connected to the ǃB-
strand by the long RT loop, which contain the ALY(F)DY(F) motif. The loops connecting 
strands ǃB and ǃC and strands ǃC and ǃD are called N-Src and Distal loop, respectively. 
The ǃC strand contains the WW dipeptide motif. After the ǃD strand, the polypeptide chain 
adopts a 310 helix containing the PxxY motif that connects ǃD and ǃE strands (Marchiani, 
2009; and references therein). 
Crystal and solution structures of SH3 domain-ligand complexes reveal that the SH3 region 
involved in the interaction with the proline-rich peptide is a surface patch formed by the 
side chains of a few well-conserved residues: 1) one of the two aromatic residues in the 
ALY(F)DY(F) motif; 2) the first tryptophan of the WW dipeptide; 3) the PxxY motif. These 
residues are aligned to form a surface patch, quite hydrophobic, in which the aromatic side 
chains are stacked against each other (Figure 8). 
The majority of SH3 domains recognize proline-rich peptides that adopt a left-handed poly-
proline type II (PPII) helix containing two XP dipeptides, separated by a scaffolding residue 
(often a proline), forming the XPxXP core element (Feng, 1994). A basic residue, Lys or more 
frequently an Arg, is present either at the N-terminal or at the C-terminal to the XPxXP 
motif, permitting to classify Pro-rich ligands into two distinct groups named classes I and II, 
respectively. 
The capability to recognize Lys or Arg residue into the binding motif is a selectivity 
mechanism found in SH3-ligands. For example, the Crk SH3 domain is selective for class II 
peptide-ligands containing a Lys residue (Knudsen, 1995). High resolution crystal structures 
of this domain bound to proline-rich peptides containing either lysine or arginine residue 
shown that while the lysine side-chain is in a extended configuration and the ε-amino group 
makes strong hydrogen bonds with three acidic residues (Asp147, Glu149 and Asp150), the 
arginine side chain does not adopt a low energy extended configuration and is involved in 
only two hydrogen-bonding interactions with proteins (Wu, 1995). 
Structural analysis of either class I or class II peptides – SH3 complexes showed that these 
two ligand classes bind to SH3 domains in opposite orientations at the same binding site. 
The fact that ligands can bind either N-to-C or C-to-N orientations is a consequence of the 
two-fold rotational pseudo-symmetry possessed by the left-handed PPII helix (Siligardi & 
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Drake, 1995). This apparent ambiguity is resolved by the observation that important 
determinant for the binding to the two XP pockets is the surface presented by the alkylated 
amide nitrogen of the proline residue, and the carbonyl, the ǂ-carbon and the side-chain of 
the preceding residue (Fernandez-Ballester, 2004). 
 
Fig. 8. The interactions occurring between the N-terminal SH3 domain of c-Crk and a lysine-
containing proline-rich peptide are shown (PDB file 1CKA). The the ligand-peptide is 
highlighted in yellow. The aromatic surface patch is depicted in red, while the anionic side 
chain of the Asp and Glu residues involved in the interaction with the Lys residue in cyan. 
The Figure was drawn using the program PYMOL (K.L. DeLano, www.pymol.org). 
Studies on the SH3 Fyn tyrosine kinase domain revealed that the Trp residue in the binding 
pocket can adopt two different orientations, determining the type of ligand able to bind to 
the domain. The motion of this residue is closely related to the presence of specific residues 
located in a key position; e.g. the residue numbering 132 of Fyn. When the conserved Trp 
residue can move, upon ligand binding, the structural conformation of the ligand fixes the 
conserved Trp either to SH3 class I or class II orientations. Unlike, when the motion of 
conserved Trp is hindered, the SH3 domain invariably presents the conserved Trp residue in 
a SH3 class II orientation, either in free or ligand-bound state (Fernandez-Ballester, 2004). 
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A recent finding demonstrated as some SH3 domains recognized not only the XPxXP 
sequences but that also other contacts are involved in the recruitment (Li, 2005), which 
may be classified into three arbitrary categories: (1) interactions that involve the XPxXP-
motif docking surface of the SH3 domain to a peptide that does not conform to a classic 
XPxXP consensus; (2) interactions that do not involve the XPxXP-motif docking surface of 
the SH3 domain and (3) complex interactions, which may or may not involve residues 
contributing to the PxxP docking surface, but differ strongly from typical SH3 target 
peptide recognition. 
4. Conclusion 
The focus of medicinal chemistry is on the design of molecules that can manipulate disease-
related biological targets for beneficial effects with low toxicity. As we have seen, peptides 
show great potential as both active drugs and diagnostics. The discovery and development 
of peptide-based drugs have both rational and empirical aspects. Random screening 
procedures can be used to identify ligands for known functional domains of target proteins, 
which can be followed by successive structural and computational analysis.  
The principal medicinal chemistry challenges for a peptide chemist are to design molecules 
characterized by a sufficient duration of action, sufficient receptor specificity, and a both 
stable and appropriate formulation. Recently, studies of self-organizing peptides (amyloids) 
yielded important information for the development of long-acting peptides. Peptide 
constraint has been used both to prevent proteolysis and to bias binding toward particular 
receptor subtypes. The latter activity appears still to be evolving into a rational design 
approach but still requires attention to an appropriate strategy for successful commercial 
development.  
Many of these issues are reminiscent of the “rocky road” which other biotecnology drugs, 
e.g., monoclonal antibodies, had to take before they became a commercial success. However, 
the development of peptides into tools for diagnostic purposes and drugs, based on their 
specificity of target recognition and their versatility of mechanisms, offers enormous 
promise. While peptides as drugs is a concept that still involves considerable challenge, 
encouragement may be gleaned from the words of Arthur C. Clarke (1917 – 2008) “...we do 
not have all the answers, but we have plenty of questions certainly worth thinking about; 
and when the technology is finally sufficiently advanced it is indistinguishable from magic”.  
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